Online inquiry

IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2008MR)

This product GTTS-WQ2008MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets INSR gene. The antibody can be applied in Hunter syndrome (MPS II) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000208.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3643
UniProt ID P06213
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2008MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12250MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ2650MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ914MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ9512MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J2898A
GTTS-WQ7466MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ10244MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ8971MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ2110MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW